SIRPA and visceral leishmaniasis: Further studies will be required to ascertain the long-term impact of disrupting SIRPα–CD47 interactions for the progression of experimental visceral leishmaniasis, and to determine the breadth of infections in which regulated expression of SIRPα may similarly provide a mechanism for breaking hepatic tolerance.